Brokerages Set Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Price Target at $17.20

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has received an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.20.

SENS has been the topic of several analyst reports. HC Wainwright reduced their price target on shares of Senseonics Holdings, Inc. Common Stock from $18.50 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. Mizuho decreased their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Weiss Ratings lowered shares of Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th.

Senseonics Holdings, Inc. Common Stock Stock Down 3.1%

Shares of SENS opened at $9.33 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 6.40 and a current ratio of 6.74. Senseonics Holdings, Inc. Common Stock has a one year low of $4.79 and a one year high of $11.58. The stock has a market capitalization of $390.02 million, a price-to-earnings ratio of -4.18 and a beta of 1.08. The stock has a 50 day moving average price of $6.88 and a 200 day moving average price of $6.69.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.08). The business had revenue of $14.48 million for the quarter. Senseonics Holdings, Inc. Common Stock had a negative return on equity of 165.80% and a negative net margin of 225.09%. Equities research analysts forecast that Senseonics Holdings, Inc. Common Stock will post -2.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Senseonics Holdings, Inc. Common Stock

In related news, Director Douglas Roeder bought 13,953 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average price of $8.98 per share, for a total transaction of $125,297.94. Following the acquisition, the director owned 171,191 shares of the company’s stock, valued at approximately $1,537,295.18. This trade represents a 8.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 4.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SENS. Kestra Advisory Services LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the first quarter valued at approximately $68,000. GSK plc acquired a new position in Senseonics Holdings, Inc. Common Stock during the fourth quarter worth $60,000. The Manufacturers Life Insurance Company acquired a new stake in Senseonics Holdings, Inc. Common Stock in the second quarter valued at $65,000. State of Wyoming purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 2nd quarter worth $67,000. Finally, Cetera Investment Advisers purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock during the 1st quarter worth $85,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.